Judith E Karp

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. pmc Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features
    Judith E Karp
    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231 1000, USA
    Clin Cancer Res 14:3077-82. 2008
  2. pmc Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias
    Judith E Karp
    Division of Hematologic Malignancies, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Hospital, Baltimore, Maryland 21287, USA
    Clin Cancer Res 18:6723-31. 2012
  3. pmc Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia
    Judith E Karp
    Division of Hematologic Malignancies, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland 21231 1000, USA
    Haematologica 97:1736-42. 2012
  4. pmc Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia
    Judith E Karp
    Division of Hematologic Malignancies, John Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231 1000, USA
    Blood 119:55-63. 2012
  5. pmc Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia
    Mitch Raponi
    Veridex, LLC, Johnson and Johnson Company, San Diego, CA 9212, USA
    BMC Cancer 4:56. 2004
  6. ncbi request reprint Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia
    Judith E Karp
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231 1000, USA
    Clin Cancer Res 13:4467-73. 2007
  7. pmc Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia
    Judith E Karp
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    Leuk Res 34:877-82. 2010
  8. ncbi request reprint Trying to improve clinical outcome in AML: lessons from negative trials
    Judith E Karp
    Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting Blaustein Cancer Research Building, 1650 Orleans Street, Room 289, Baltimore, Maryland 21231 1000, USA
    Leuk Res 29:603-4. 2005
  9. pmc Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide
    Judith E Karp
    Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD 21231 1000, USA
    Blood 113:4841-52. 2009
  10. ncbi request reprint Farnesyl transferase inhibition in hematologic malignancies
    Judith E Karp
    Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Harry and Jeanette Weinberg Building, Suite 1100, 401 North Broadway, Baltimore, MD 21231, USA
    J Natl Compr Canc Netw 3:S37-40. 2005

Detail Information

Publications76

  1. pmc Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features
    Judith E Karp
    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231 1000, USA
    Clin Cancer Res 14:3077-82. 2008
    ..Tipifarnib is an oral farnesyltransferase inhibitor with activity in AML. We conducted a phase II trial of maintenance tipifarnib monotherapy for 48 adults with poor-risk AML in first CR...
  2. pmc Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias
    Judith E Karp
    Division of Hematologic Malignancies, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Hospital, Baltimore, Maryland 21287, USA
    Clin Cancer Res 18:6723-31. 2012
    ..To extend these findings to the clinical setting, we have conducted a phase I study of cytarabine and SCH 900776...
  3. pmc Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia
    Judith E Karp
    Division of Hematologic Malignancies, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland 21231 1000, USA
    Haematologica 97:1736-42. 2012
    ..6 months...
  4. pmc Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia
    Judith E Karp
    Division of Hematologic Malignancies, John Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231 1000, USA
    Blood 119:55-63. 2012
    ..The next T-based clinical trials will test the ability of the 2-gene signature to enrich for T responders prospectively. This study is registered at www.clinicaltrials.gov as #NCT00602771...
  5. pmc Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia
    Mitch Raponi
    Veridex, LLC, Johnson and Johnson Company, San Diego, CA 9212, USA
    BMC Cancer 4:56. 2004
    ..This study was conducted to identify genetic markers and pathways that are regulated by tipifarnib in acute myeloid leukemia (AML)...
  6. ncbi request reprint Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia
    Judith E Karp
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231 1000, USA
    Clin Cancer Res 13:4467-73. 2007
    ..We have now completed a phase II study of sequential flavopiridol, ara-C, and mitoxantrone in 62 adults with poor-risk AML...
  7. pmc Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia
    Judith E Karp
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    Leuk Res 34:877-82. 2010
    ..Short OS and DFS correlated with adverse cytogenetics, regardless of age or treatment in CR. The addition of allogeneic BMT in CR translates into long OS and DFS in the majority of eligible patients...
  8. ncbi request reprint Trying to improve clinical outcome in AML: lessons from negative trials
    Judith E Karp
    Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting Blaustein Cancer Research Building, 1650 Orleans Street, Room 289, Baltimore, Maryland 21231 1000, USA
    Leuk Res 29:603-4. 2005
  9. pmc Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide
    Judith E Karp
    Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD 21231 1000, USA
    Blood 113:4841-52. 2009
    ..These clinical studies are registered at www.clinicaltrials.gov as #NCT00112853...
  10. ncbi request reprint Farnesyl transferase inhibition in hematologic malignancies
    Judith E Karp
    Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Harry and Jeanette Weinberg Building, Suite 1100, 401 North Broadway, Baltimore, MD 21231, USA
    J Natl Compr Canc Netw 3:S37-40. 2005
  11. ncbi request reprint Targeting the process of farynesylation for therapy of hematologic malignancies
    Judith E Karp
    The Sidney Kimmel Cancer Center at Johns Hopkins, 1650 Orleans St, Bunting Blaustein Cancer Research Bldg, Room 289, Baltimore, Maryland 21231 1000, USA
    Curr Mol Med 5:643-52. 2005
    ..What we learn about FTIs in the clinic and the laboratory will apply broadly to the effective and safe application of all signal transduction inhibitors...
  12. ncbi request reprint Development of farnesyltransferase inhibitors for clinical cancer therapy: focus on hematologic malignancies
    Judith E Karp
    Division of Hematologic Malignancies, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland 21231, USA
    Cancer Invest 25:484-94. 2007
    ..Clinical trials and correlative laboratory studies in progress and under development will define the optimal roles of FTIs in cancer patients...
  13. ncbi request reprint Development of the farnesyltransferase inhibitor tipifarnib for therapy of hematologic malignancies
    Judith E Karp
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Division of Hematologic Malignancies, The Bunting Blaustein Cancer Research Building, Baltimore, MD 21231, USA
    Future Oncol 1:719-31. 2005
    ..The full development of FTIs for the therapy of hematologic malignancies will require the design and testing of rational combinations of cytotoxic, biologic and immunomodulatory agents in the laboratory and the clinic...
  14. pmc A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloprol
    Judith E Karp
    Leukemia Program, Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    Leuk Res 32:71-7. 2008
    ..Drug-related toxicities included fever and metabolic acidosis. Triapine 105 mg/m(2) followed by fludarabine 30 mg/m2 daily x 5 is active in refractory myeloid malignancies and warrants continuing study for patients with aggressive MPD...
  15. pmc A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias
    Judith E Karp
    Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    Blood 110:1762-9. 2007
    ..This clinical trial is registered with the National Cancer Institute's PDQ at www.clinicaltrials.gov as no. JHOC-J0561...
  16. ncbi request reprint Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab
    Judith E Karp
    University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, USA
    Clin Cancer Res 10:3577-85. 2004
    ..We conducted a Phase II clinical trial of bevacizumab administered after chemotherapy to adults with refractory or relapsed AML, using a timed sequential therapy (TST) approach...
  17. ncbi request reprint Timed sequential therapy of acute leukemia with flavopiridol: in vitro model for a phase I clinical trial
    Judith E Karp
    University of Maryland Greenebaum Cancer Center, Baltimore, Maryland 2120, USA
    Clin Cancer Res 9:307-15. 2003
    ..trigger apoptosis in fresh acute leukemia; and (b). recruit surviving leukemic cells to a proliferative state, thereby priming such cells for the S-phase-related cytotoxicity of 1-beta-D-arabinofuranosylcytosine (ara-C)...
  18. pmc Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias
    Judith E Karp
    Division of Hematologic Malignancies, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231 1000, USA
    Blood 117:3302-10. 2011
    ..This clinical trial is registered at www.clinicaltrials.gov as #NCT00470197...
  19. ncbi request reprint Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias
    Judith E Karp
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    Clin Cancer Res 11:8403-12. 2005
    ....
  20. pmc Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemias
    Amer M Zeidan
    Division of Hematologic Malignancies, Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Br J Haematol 158:198-207. 2012
    ..In summary, the CLO-CYx4 regimen was well tolerated and had activity in patients with RRAL, especially relapsed ALL. Therefore, CLO-CYx4 can be considered a salvage therapy for adults with RRALs, and warrants further investigations...
  21. ncbi request reprint Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies
    Ivana Gojo
    University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD 21201, USA
    Leuk Res 31:1165-73. 2007
    ..2-5.5 microM) was above levels required to achieve in vitro/in vivo leukemia growth inhibition. Based on these data, we conclude that Triapine warrants further investigation in hematologic malignancies...
  22. ncbi request reprint Durable molecular remissions with a single cycle of timed sequential consolidation chemotherapy in acute promyelocytic leukemia
    Steven D Gore
    The Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Am J Hematol 79:119-27. 2005
    ..However, the toxicity of the consolidation module and the development of secondary myelodysplasia despite decreased total therapy emphasize the need to further improve and refine curative therapy for APL...
  23. pmc Effects of selective checkpoint kinase 1 inhibition on cytarabine cytotoxicity in acute myelogenous leukemia cells in vitro
    Erin L Schenk
    Department of Oncology, Mayo Clinic, Rochester, MN, USA
    Clin Cancer Res 18:5364-73. 2012
    ..Long-term effects in AML lines, clinical AML isolates, and normal myeloid progenitors were assayed using clonogenic assays...
  24. ncbi request reprint Quantitative analysis of breast cancer resistance protein and cellular resistance to flavopiridol in acute leukemia patients
    Takeo Nakanishi
    Department of Medicine, Division of Hematology Oncology, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    Clin Cancer Res 9:3320-8. 2003
    ..In vitro cell viability and apoptosis were examined after 24 h exposure to flavopiridol...
  25. pmc Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia
    Elizabeth A Griffiths
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Epigenetics 5:590-600. 2010
    ..Methylation of tumor suppression genes (TSGs) is common in myeloid malignancies. However, application of this as a molecular marker for risk stratification in patients with AML is limited...
  26. ncbi request reprint A phase II study of timed sequential therapy of acute myelogenous leukemia (AML) for patients over the age of 60: two cycle timed sequential therapy with topotecan, ara-C and mitoxantrone in adults with poor-risk AML
    Javier Bolaños-Meade
    University of Maryland Greenebaum Cancer Center, Baltimore, MD 21201, USA
    Leuk Res 28:571-7. 2004
    ..9-25.3 months). There were no differences in OS or DFS between cytogenetic or disease etiology groups. Although TST was well tolerated, long-term results in this group of patients are not satisfactory and new approaches are needed...
  27. pmc Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias
    Ivana Gojo
    University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD 21201, USA
    Blood 109:2781-90. 2007
    ..No responses by classical criteria were seen. Our results show that MS-275 effectively inhibits HDAC in vivo in patients with advanced myeloid leukemias and should be further tested, preferably in patients with less-advanced disease...
  28. doi request reprint Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation
    Elizabeth A Griffiths
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Leuk Lymphoma 51:1711-9. 2010
    ....
  29. pmc Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies
    Ying Ye
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Cancer Res 69:8482-90. 2009
    ....
  30. pmc Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells
    Christopher G Kanakry
    Division of Hematologic Malignancies, The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA
    Blood 117:608-17. 2011
    ..Further insight into this oligoclonal regulatory T-cell population will be fundamental toward developing effective immunomodulatory techniques to improve survival for patients with AML...
  31. ncbi request reprint Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms
    Steven D Gore
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21287, USA
    Cancer Res 66:6361-9. 2006
    ..The promising percentage of major hematologic responses justifies the testing of such combinations in prospective randomized trials...
  32. ncbi request reprint Timed sequential therapy of acute myelogenous leukemia in adults: a phase II study of retinoids in combination with the sequential administration of cytosine arabinoside, idarubicin and etoposide
    Javier Bolaños-Meade
    University of Maryland Greenebaum Cancer Center, 22 South Greene Street, Room S9D07, Baltimore, MD 21201, USA
    Leuk Res 27:313-21. 2003
    ..However, patients of age equal to 60 years and those with poor-risk disease features still have poor CR and DFS, despite the addition of ATRA...
  33. ncbi request reprint A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia
    Kenneth S Bauer
    Greenebaum Cancer Center, University of Maryland School of Pharmacy, Allied Health Building Suite 540, 100 Penn Street, Baltimore, MD 21201, USA
    Leuk Res 29:263-71. 2005
    ..This combination including PSC-833 was well tolerated. Although a pharmacokinetic interaction might have been expected, PSC-833 did not significantly alter the disposition of idarubicin...
  34. ncbi request reprint Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization
    Xue Wei Meng
    Divisions of Oncology Research, Department of Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    J Biol Chem 282:29831-46. 2007
    ..Collectively, these observations not only suggest a model in which Mcl-1 confers TRAIL resistance by serving as a buffer for Bak, Bim, and Puma, but also identify sorafenib as a potential modulator of TRAIL sensitivity...
  35. ncbi request reprint New agents in the treatment of acute myeloid leukemia: a snapshot of signal transduction modulation
    Ting Bao
    Johns Hopkins School of Medicine, Baltimore, MD 21231, USA
    Clin Adv Hematol Oncol 3:287-96, 302. 2005
    ..This review will focus on several exciting components of these pathways and the agents targeting these pathways that are entering clinical trials...
  36. pmc A rapid and sensitive method for determination of veliparib (ABT-888), in human plasma, bone marrow cells and supernatant by using LC/MS/MS
    Sarah Reinhardt
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, United States
    J Pharm Biomed Anal 52:122-8. 2010
    ....
  37. pmc New agents in acute myeloid leukemia: beyond cytarabine and anthracyclines
    Amir T Fathi
    Division of Hematologic Malignancies, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, 1650 Orleans Street, CRB 1 Room 289, Baltimore, MD 21231, USA
    Curr Oncol Rep 11:346-52. 2009
    ....
  38. pmc What are the endpoints of therapy for acute leukemias? Old definitions and new challenges
    B Douglas Smith
    Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    Clin Lymphoma Myeloma 9:S296-301. 2009
    ....
  39. pmc The clinically relevant pharmacogenomic changes in acute myelogenous leukemia
    Ashkan Emadi
    University of Maryland, School of Medicine, Marlene and Stewart Greenebaum Cancer Center, Leukemia and Hematologic Malignancies, Baltimore, MD 21201, USA
    Pharmacogenomics 13:1257-69. 2012
    ....
  40. pmc Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution
    Amy E Dezern
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Biol Blood Marrow Transplant 17:1404-9. 2011
    ..Our single-institution study of consecutively treated AML patients supports the hypothesis that allogeneic transplant in early CR1 improves the long-term outcomes for FLT3/ITD AML...
  41. pmc Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF
    B Douglas Smith
    Johns Hopkins Medical Institute, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, USA
    Leuk Res 35:87-94. 2011
    ..We developed a dose finding trial to assess toxicity, differentiating activity, and clinical impact of the combination of bryostatin-1 and GM-CSF...
  42. doi request reprint Poly(ADP-ribose) polymerase inhibitor CEP-8983 synergizes with bendamustine in chronic lymphocytic leukemia cells in vitro
    Robert L Dilley
    Department of Oncology and the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA
    Leuk Res 38:411-7. 2014
    ..Our results provide rationale for further exploration of the combination of a PARP inhibitor and DNA damaging agents as a novel therapeutic strategy in CLL. ..
  43. pmc A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response
    Keith W Pratz
    Department of Oncology, Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Blood 113:3938-46. 2009
    ....
  44. pmc Flavopiridol induces BCL-2 expression and represses oncogenic transcription factors in leukemic blasts from adults with refractory acute myeloid leukemia
    Dwella M Nelson
    Division of Hematology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Leuk Lymphoma 52:1999-2006. 2011
    ..Although further studies are needed, our findings also suggest that blocking anti-apoptotic pathways could enhance cytotoxicity with flavopiridol...
  45. pmc Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors
    Mark Levis
    Kimmel Cancer Center at Johns Hopkins University, Baltimore, MD 21231, USA
    Blood 108:3477-83. 2006
    ..Additionally, our results suggest that nonselectivity may constitute an important component of the cytotoxic effect of FLT3 inhibitors in FLT3-mutant AML...
  46. ncbi request reprint Curing acute myelogenous leukemia: still a major challenge
    B Douglas Smith
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Leuk Res 29:607-8. 2005
  47. pmc A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia
    Jonathan M Gerber
    Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Blood 119:3571-7. 2012
    ..ALDH activity appears to distinguish normal from leukemic CD34(+)CD38(-) cells and identifies those AML cells associated with relapse...
  48. ncbi request reprint Overcoming drug resistance: targeting more than one site
    Judith E Karp
    Greenebaum Cancer Center, University of Maryland, Baltimore, MD 21201, USA
    Leuk Res 26:107-9. 2002
  49. ncbi request reprint Ribonucleotide reductase: an old target with new potential
    B Douglas Smith
    Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, MD 21210, USA
    Leuk Res 27:1075-6. 2003
  50. pmc Performance and clinical evaluation of a sensitive multiplex assay for the rapid detection of common NPM1 mutations
    Michael Hafez
    Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    J Mol Diagn 12:629-35. 2010
    ..Its high analytical sensitivity further suggests potential utility for the monitoring of residual disease in AML with normal karyotype...
  51. ncbi request reprint Development of therapeutic agents for older patients with acute myelogenous leukemia
    Christopher S Hourigan
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Baltimore, MD 21231 1000, USA
    Curr Opin Investig Drugs 11:669-77. 2010
    ....
  52. pmc Exploiting cellular pathways to develop new treatment strategies for AML
    Amir T Fathi
    Division of Hematologic Malignancies, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, 1650 Orleans Street, Baltimore, MD 21231, USA
    Cancer Treat Rev 36:142-50. 2010
    ..In this review, we aim to provide a summary of the preclinical and clinical investigations of selected promising agents currently under study...
  53. pmc Personalized therapy for acute myeloid leukemia
    Christopher S Hourigan
    1Myeloid Malignancies Section, Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, and 2The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
    Cancer Discov 3:1336-8. 2013
    ....
  54. pmc Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia
    Judith E Karp
    Division of Hematologic Malignancies, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA
    Biologics 2:491-500. 2008
    ..The clinical and correlative laboratory trials in progress and under development will provide the critical foundations for defining the optimal roles of tipifarnib and in patients with AMl and other hematologic malignancies...
  55. ncbi request reprint Epigenetic and genetic loss of Hic1 function accentuates the role of p53 in tumorigenesis
    Wenyong Chen
    Cancer Biology Program, Johns Hopkins Medical Institutions, 1650 Orleans Street, Baltimore, MD 21231, USA
    Cancer Cell 6:387-98. 2004
    ..Our results indicate the importance of genes altered only through epigenetic mechanisms in cancer progression in conjunction with genetically modified tumor suppressor genes...
  56. ncbi request reprint Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells
    Joya Chandra
    Division of Oncology Research, Guggenheim 1301, Mayo Clinic, 200 First St, SW, Rochester, MN 55901, USA
    Blood 102:4512-9. 2003
    ....
  57. ncbi request reprint A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia
    Mitch Raponi
    Veridex, 3210 Merryfield Row, La Jolla, CA 92121, USA
    Blood 111:2589-96. 2008
    ..Therefore, these data indicate that a 2-gene expression assay may have utility in categorizing a population of patients with AML who are more likely to respond to tipifarnib...
  58. ncbi request reprint Farnesyl transferase inhibitors in myeloid malignancies
    Jeffrey E Lancet
    University of Rochester, James P Wilmot Cancer Center, 601 Elmwood Avenue, Box 704 Rochester, NY 14642, USA
    Blood Rev 17:123-9. 2003
    ....
  59. ncbi request reprint Developmental clinical trials: building one step at a time
    Judith E Karp
    Leuk Res 30:765-6. 2006
  60. ncbi request reprint Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases
    Francis J Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Cancer 97:1920-8. 2003
    ..SU5416 is a small-molecule RTK inhibitor (RTKI) that targets VEGFR-2, c-kit, and fms-related tyrosine kinase Flk2...
  61. ncbi request reprint SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes
    Francis J Giles
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 428, Houston, TX 77030, USA
    Blood 102:795-801. 2003
    ..Studies of other RTKI and/or other antiangiogenic approaches, with correlative studies to examine biologic effects, may be warranted in patients with AML/MDS...
  62. ncbi request reprint Farnesyltransferase inhibitors and myeloid malignancies: phase I evidence of Zarnestra activity in high-risk leukemias
    Jeffrey E Lancet
    University of Rochester, James P Wilmot Cancer Center, Rochester, NY, USA
    Semin Hematol 39:31-5. 2002
    ..These results suggest that Zarnestra should be studied further in patients with myeloid leukemia...
  63. ncbi request reprint Regulation of leukemic cell adhesion, proliferation, and survival by beta-catenin
    Eun Joo Chung
    Medical Oncology Clinical Research Unit and Developmental Therapeutics Program, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 100:982-90. 2002
    ..Fas-mediated apoptosis was potentiated by inhibition of beta-catenin nuclear signaling. The data suggest that beta-catenin can play a significant role in promoting leukemic cell proliferation, adhesion, and survival...
  64. pmc A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia
    Jeffrey E Lancet
    H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL 33612, USA
    Blood 109:1387-94. 2007
    ..Tipifarnib is active and well tolerated in older adults with poor-risk AML and may impart a survival advantage in those patients who experience a clinical response...
  65. ncbi request reprint Histone deacetylase inhibitor pharmacodynamic analysis by multiparameter flow cytometry
    Eun Joo Chung
    Medical Oncology Clinical Research Unit, Bethesda, MD 20892, USA
    Ann Clin Lab Sci 35:397-406. 2005
    ..The technique described has significant advantages for the PD assessment of HDAC inhibitors as monotherapy and as a component of combination therapy trials...
  66. ncbi request reprint Farnesyl transferase inhibitors in myeloid disorders
    Jeffrey E Lancet
    H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida 33612, USA
    Oncology (Williston Park) 19:1043-9; discussion 1049-50, 1053-4. 2005
    ....
  67. ncbi request reprint Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia
    Anne Marie O'Farrell
    SUGEN Inc, South San Francisco, CA, USA
    Leuk Res 28:679-89. 2004
    ..The translational and clinical analyses described in this report provide some insights into the mechanism and duration of action of SU5416...
  68. ncbi request reprint Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemia
    Scott H Kaufmann
    Division of Hematology, Department of Medicine, Mayo Clinic College of Medicine, Rochester, MN 55901, USA
    Clin Cancer Res 11:6641-9. 2005
    ..To assess the maximum tolerated dose, toxicities, pharmacokinetics, and antileukemic activity of topotecan and carboplatin in adults with recurrent or refractory acute leukemias...
  69. ncbi request reprint Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy
    Jeffrey E Lancet
    James P Wilmot Cancer Center, University of Rochester, 601 Elmwood Ave, Box 704, Rochester, NY 14642, USA
    Blood 102:3880-9. 2003
    ..It is anticipated that these studies will serve to define the optimal roles of FTIs in patients with hematologic malignancies and provide insight into effective methods by which to combine FTIs with other agents...
  70. ncbi request reprint Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer
    Milin R Acharya
    Clinical Pharmacology Research Core, National Cancer Institute, Bethesda, MD, USA
    Invest New Drugs 24:367-75. 2006
    ..To evaluate elimination pathways of the histone deacetylase inhibitor MS-275 in vitro and screen for relationships between demographic factors that may affect its pharmacokinetics in vivo...
  71. pmc Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine
    Ruben A Mesa
    Division of Hematology, Department of Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Blood 106:318-27. 2005
    ..Collectively, these results suggest that treatment with 17-AAG might represent a means of reversing checkpoint-mediated cytarabine resistance in AML...
  72. ncbi request reprint Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome
    Joshua Wechsler
    Ben May Institute for Cancer Research, University of Chicago, Chicago, Illinois 60637, USA
    Nat Genet 32:148-52. 2002
    ..Together, these findings indicate that loss of wildtype GATA1 constitutes one step in the pathogenesis of AMKL in Down syndrome...
  73. ncbi request reprint Central role of Fas-associated death domain protein in apoptosis induction by the mitogen-activated protein kinase kinase inhibitor CI-1040 (PD184352) in acute lymphocytic leukemia cells in vitro
    Xue Wei Meng
    Division of Oncology Research, Guggenheim 1342C, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    J Biol Chem 278:47326-39. 2003
    ..Collectively, these results identify the MAPK pathway as a potential therapeutic target in ALL and delineate a mechanism by which MEK inhibition triggers apoptosis in ALL cells...
  74. doi request reprint The long road to a cure for acute myelocytic leukemia: from intensity to specificity
    William P Vaughan
    University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA
    J Clin Oncol 26:3475-7. 2008
  75. ncbi request reprint Genomic mechanisms of p210BCR-ABL signaling: induction of heat shock protein 70 through the GATA response element confers resistance to paclitaxel-induced apoptosis
    Sutapa Ray
    Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas 77555 1060, USA
    J Biol Chem 279:35604-15. 2004
    ..We suggest that down-regulation of the GATA-Hsp70 pathway may be useful in the treatment of chemotherapy-resistant CML...
  76. ncbi request reprint Exploiting oxidative damage to overcome resistance
    Judith E Karp
    Leuk Res 30:1213-4. 2006